TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) shares fell 8.1% on Wednesday . The company traded as low as $0.66 and last traded at $0.68. 1,056,975 shares changed hands during mid-day trading, a decline of 20% from the average session volume of 1,324,074 shares. The stock had previously closed at $0.74.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price objective on shares of TransCode Therapeutics in a report on Friday, September 6th.
View Our Latest Analysis on RNAZ
TransCode Therapeutics Stock Up 2.5 %
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.16). Sell-side analysts predict that TransCode Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.
Institutional Investors Weigh In On TransCode Therapeutics
An institutional investor recently bought a new position in TransCode Therapeutics stock. Virtu Financial LLC bought a new position in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund bought 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned 0.84% of TransCode Therapeutics at the end of the most recent quarter.
About TransCode Therapeutics
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Featured Articles
- Five stocks we like better than TransCode Therapeutics
- NYSE Stocks Give Investors a Variety of Quality Options
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Are Penny Stocks a Good Fit for Your Portfolio?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Capture the Benefits of Dividend Increases
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.